<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053074</url>
  </required_header>
  <id_info>
    <org_study_id>NHFwake2020</org_study_id>
    <nct_id>NCT05053074</nct_id>
  </id_info>
  <brief_title>Nasal High Flow (NHF) in COPD - Effects on Ventilation in Wakefulness</brief_title>
  <official_title>Nasal High Flow (NHF) Bei COPD - Effekte Auf Die Ventilation im Wachzustand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pneumologie Hagen Ambrock eV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut für Pneumologie Hagen Ambrock eV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Controlled randomized crossover trial in patients with chronic obstructive respiratory&#xD;
      disease (COPD), who are treated with Nasal High Flow (NHF) therapy during wakefulness with a&#xD;
      small amount of CO2 added to the inhaled air to keep the patients' PaCO2 stable despite the&#xD;
      washout effect. Aim of the study is to examine respiratory rate, tidal volume and work of&#xD;
      breathing under NHF without the CO2 washout effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this controlled randomized crossover trial, 10 stable patients with chronic obstructive&#xD;
      respiratory disease (COPD) are treated with Nasal High Flow (NHF) therapy during wakefulness.&#xD;
      NHF treatment will inevitably result in increased upper airway washout and thus in a slight&#xD;
      reduction of PaCO2 of approximately 2 mmHg. For compensation, a small amount of CO2 is added&#xD;
      to the inhaled air during this experimental situation, which keeps the patients' PaCO2&#xD;
      stable. This will allow to examine the effects of NHF therapy on respiratory rate, tidal&#xD;
      volume and work of breathing, that are not attributable to the CO2 washout effect.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minute Ventilation</measure>
    <time_frame>up to 1 hour</time_frame>
    <description>Difference in the decrease of respiratory minute volume under NHF versus NHF plus CO2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tidal Volume</measure>
    <time_frame>up to 1 hour</time_frame>
    <description>Difference in the decrease in tidal volume (VT) under NHF versus NHF plus CO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>up to 1 hour</time_frame>
    <description>Difference in respiratory rate decrease under NHF versus NHF plus CO2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcutaneous pCO2</measure>
    <time_frame>up to 1 hour</time_frame>
    <description>Difference in the decrease in transcutaneous CO2 under NHF versus NHF plus CO2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with chronic respiratory failure are treated with nasal high flow during wakefulness. First with NHF (30l/min) alone, then NHF (30l/min) plus 1% CO2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with chronic respiratory failure are treated with nasal high flow during wakefulness. First with NHF (30l/min) plus 1% CO2 , then NHF (30l/min) alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal High Flow (NHF)</intervention_name>
    <description>Patients with chronic respiratory failure are treated for 1 h with NHF therapy and with individual O2 supplementation during wakefulness.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>AIRVO2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized COPD patients GOLD (3 and 4) in stable phase after an acute exacerbation.&#xD;
&#xD;
          -  Written informed consent is required for participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute respiratory failure with clinical instability or respiratory acidosis defined by&#xD;
             pH&lt;7.35&#xD;
&#xD;
          -  Severe acute physical illness that does not allow the subject to participate in a&#xD;
             clinical trial&#xD;
&#xD;
          -  Unable to give consent&#xD;
&#xD;
          -  Language, cognitive, or other impairments that may prevent independent completion of&#xD;
             questionnaires&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Nilius, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evang. Kliniken Essen-Mitte gGmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulrike Domanski</last_name>
    <phone>+492331974</phone>
    <phone_ext>2080</phone_ext>
    <email>ulrike.domanski@vamed-gesundheit.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maik Schroeder</last_name>
    <phone>+49201174</phone>
    <phone_ext>22057</phone_ext>
    <email>m.schroeder@kem-med.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Evang. Kliniken Essen-Mitte gGmbH</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45276</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Nilius, Professor</last_name>
      <phone>+49201174</phone>
      <phone_ext>22001</phone_ext>
      <email>g.nilius@kem-med.com</email>
    </contact>
    <contact_backup>
      <last_name>Maik Schroeder</last_name>
      <phone>+49201174</phone>
      <phone_ext>22057</phone_ext>
      <email>m.schroeder@kem-med.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut für Pneumologie Hagen Ambrock eV</investigator_affiliation>
    <investigator_full_name>Georg Nilius, Prof DR med</investigator_full_name>
    <investigator_title>Clinical Director</investigator_title>
  </responsible_party>
  <keyword>Nasal High Flow</keyword>
  <keyword>PaCO2</keyword>
  <keyword>Tidal Volume</keyword>
  <keyword>Washout Effect</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

